Joseph Wu

Joseph C. Wu, MD, PhD, Simon H. Stertzer, MD Professor, Departments of Medicine and Radiology; Director, Stanford Cardiovascular Institute (CVI), Stanford University School of Medicine

 

Research Description: Dr. Wu’s research in cardiovascular biology and medicine has focused on the areas of (i) disease modeling, (ii) precision medicine, (iii) pharmacogenomics and drug discovery, (iv) stem cell biology, and (v) cardiovascular clinical trials. Using diverse approaches including molecular and cellular biology, genetics, tissue engineering, and molecular imaging technologies, his group has made seminal discoveries in these areas related to cardiovascular medicine. Building on these successes, his group has further launched efforts to investigate areas related to diabetes, including patient-specific myocardial and endothelial response to diabetic drugs. In particular, patient-specific induced pluripotent stem cell (iPSC) derivatives are being used to explore pharmacogenomics and to accelerate drug discovery in diabetes. As CVI director, Dr. Wu sponsored support of several Stanford DRC projects in the Pilot and Feasibility Award competition. He is also PI of a Stanford T32 grant on cardiovascular imaging, which has also supported diabetes research by Stanford trainees. Dr. Wu serves on the Stanford DRC Executive Committee.

Selected relevant publications (Stanford DRC Members in BOLD):

1.     Matsa E, Burridge PW, Yu KH, Ahrens JH, Termglinchan V, Wu H, Liu H, Shukla P, Sayed N, Churko JM, Shao N, Woo NA, Chao AS, Gold JD, Karakikes I, Snyder MP, Wu JC. Transcriptome profiling of patient-specific human iPSC-cardiomyocytes predicts individual drug safety and efficacy responses in vitro. Cell Stem Cell 2016; in press.

2.     Matsa E, Burridge PW, Wu JC. Human stem cells for modeling heart disease and drug discovery. Science Transl Med 2014;6(239):239ps6.

3.     Burridge PW, Keller G, Gold JD, Wu JC. Production of de novo cardiomyocytes: human pluripotent stem cell differentiation and direct reprogramming. Cell Stem Cell 2012;10(1):16-28.

4.     Lee AS, Tang C, Rao MS, Weissman IL, Wu JC. Tumorigenicity as a clinical hurdle for pluripotent stem cells. Nature Medicine 2013;19(8):998-1004.

5.     Pearl JI, Lee A, Leveson-Gower DB, Sun N, Ghosh Z, Lan F, Ransohoff J, Negrin RS, Davis MM, Wu JC. Short-term blockade of leukocyte costimulatory molecules promotes engraftment of embryonic and induced pluripotent stem cells. Cell Stem Cell 2011;8(3):309-17.

6.     Tang C, Lee AS, Peter-Volkmer J, Sahoo D, Mosley A, van de Rijn M, Inlay MA, Ardehali R, Wu JC, Weissman IL, Drukker M. Removal of residual teratoma-forming cells via a surface antibody panel ensures transplantation safety of human pluripotent stem cell derivatives. Nature Biotech 2011;29(9):829-34.

7.     Narsinh KH, Sun N, Sanchez-Freire V, Lee AS, Almeida P, Hu S, Jan T, Wilson KD, Leong D, Rosenberg J, Yao M, Wu JC. Single cell transcriptional profiling reveals heterogeneity of human induced pluripotent stem cells. Journal Clinical Investigation 2011;121(3):1217-21.